Safety, Pharmacokinetic, Biomarker, Histologic, and Rectal Bleeding Activity Following Treatment with the Gut-Targeted, PHD-Inhibitor and HIF-1α Stabilizer GB004 in a Phase 1b Trial in Mild-to-Moderate Ulcerative Colitis
Safety, Pharmacokinetic, Biomarker, Histologic, and Rectal Bleeding Activity Following Treatment with the Gut-Targeted, PHD-Inhibitor and HIF-1α Stabilizer GB004 in a Phase 1b Trial in Mild-to-Moderate Ulcerative Colitis
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
